I-Mab, a global biotech company focused on precision immuno-oncology agents for cancer treatment, reported its financial results for the second quarter of 2025. The company recorded a net loss of $5.5 million for the three months ended June 30, 2025, compared to a net income of $25.4 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $8.7 million, a change from a net income of $9.1 million in the previous year. The net loss from continuing operations was $5.5 million for the second quarter of 2025, improving slightly from a loss of $8.9 million in the same quarter of 2024. For the six months ended June 30, 2025, the net loss from continuing operations was $8.7 million, compared to a loss of $18.4 million for the same period in 2024. I-Mab also reported significant progress in its pipeline, highlighting positive Phase 1b dose escalation data for givastomig in combination with immunochemotherapy in patients with first-line gastric cancers, demonstrating an 83% overall response rate. The company is planning a dose expansion study with topline data expected in the first quarter of 2026. Additionally, I-Mab strengthened its balance sheet with net proceeds of approximately $61.2 million from an August 2025 underwritten offering, resulting in a pro-forma cash balance of approximately $226.8 million as of June 30, 2025. This cash position is expected to support planned operating expenses and capital expenditures through the fourth quarter of 2028.